Zhejiang Starry Pharmaceutical Co.,Ltd.

SHSE:603520 Voorraadrapport

Marktkapitalisatie: CN¥3.8b

Zhejiang Starry PharmaceuticalLtd Inkomsten in het verleden

Verleden criteriumcontroles 1/6

Zhejiang Starry PharmaceuticalLtd's earnings have been declining at an average annual rate of -35.1%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 14.3% per year. Zhejiang Starry PharmaceuticalLtd's return on equity is 0.5%, and it has net margins of 0.6%.

Belangrijke informatie

-35.1%

Groei van de winst

-35.6%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie10.9%
Inkomstengroei14.3%
Rendement op eigen vermogen0.5%
Nettomarge0.6%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Shareholders Can Be Confident That Zhejiang Starry PharmaceuticalLtd's (SHSE:603520) Earnings Are High Quality

May 06
Shareholders Can Be Confident That Zhejiang Starry PharmaceuticalLtd's (SHSE:603520) Earnings Are High Quality

Recent updates

There's No Escaping Zhejiang Starry Pharmaceutical Co.,Ltd.'s (SHSE:603520) Muted Revenues

Sep 30
There's No Escaping Zhejiang Starry Pharmaceutical Co.,Ltd.'s (SHSE:603520) Muted Revenues

Shareholders Can Be Confident That Zhejiang Starry PharmaceuticalLtd's (SHSE:603520) Earnings Are High Quality

May 06
Shareholders Can Be Confident That Zhejiang Starry PharmaceuticalLtd's (SHSE:603520) Earnings Are High Quality

Market Might Still Lack Some Conviction On Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Even After 31% Share Price Boost

Mar 12
Market Might Still Lack Some Conviction On Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Even After 31% Share Price Boost

Is Zhejiang Starry PharmaceuticalLtd (SHSE:603520) Using Too Much Debt?

Feb 28
Is Zhejiang Starry PharmaceuticalLtd (SHSE:603520) Using Too Much Debt?

Opbrengsten en kosten

Hoe Zhejiang Starry PharmaceuticalLtd geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

SHSE:603520 Opbrengsten, kosten en inkomsten (CNY Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 242,37014256129
30 Jun 242,44332254132
31 Mar 242,27247230132
31 Dec 232,19644216135
30 Sep 232,385-56207141
30 Jun 232,273-105206136
31 Mar 232,180-147216139
31 Dec 222,131-76216133
30 Sep 222,066124208138
30 Jun 222,087232191133
31 Mar 222,153339174128
31 Dec 212,000324164125
30 Sep 211,631260159113
30 Jun 211,500255166105
31 Mar 211,44025815999
31 Dec 201,36723915488
30 Sep 201,37023114183
30 Jun 201,39521713676
31 Mar 201,30617513375
31 Dec 191,30917012878
30 Sep 191,24214614565
30 Jun 191,09812212578
31 Mar 1998811211570
31 Dec 188909410766
30 Sep 18794988470
30 Jun 18742946479
31 Mar 18712777466
31 Dec 17711838453
30 Sep 17712849635
30 Jun 17712841360
31 Mar 17698791340
31 Dec 16673761320
30 Sep 16716811350
30 Jun 16691741300
31 Mar 16661601240
31 Dec 15696691190
31 Dec 1465868910
31 Dec 1368664790

Kwaliteitswinsten: 603520 has a large one-off loss of CN¥27.4M impacting its last 12 months of financial results to 30th September, 2024.

Groeiende winstmarge: 603520 became profitable in the past.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: 603520's earnings have declined by 35.1% per year over the past 5 years.

Versnelling van de groei: 603520 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Winst versus industrie: 603520 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).


Rendement op eigen vermogen

Hoge ROE: 603520's Return on Equity (0.5%) is considered low.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden